Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firsocostat PD study in overweight/obese males
NCT02876796Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of firsocostat in Nonalcoholic steatohepatitis (NASH) (3 cohorts), sponsored by Gilead Sciences. Primary endpoints: Change in fractional de novo lipogenesis (% new palmitate), Change in DNL over time and 4 more. Started Aug 2015; status: completed.
02
Drugs
firsocostat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02876796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876796.